دورية أكاديمية
Prognostic performance of pretreatment systemic immune-inflammation index in women with epithelial ovarian cancer.
| العنوان: | Prognostic performance of pretreatment systemic immune-inflammation index in women with epithelial ovarian cancer. |
|---|---|
| المؤلفون: | Okunade KS; Department of Obstetrics & Gynaecology, College of Medicine, University of Lagos, Surulere, Lagos, Nigeria.; Department of Obstetrics & Gynaecology, Lagos University Teaching Hospital, Surulere, Lagos, Nigeria.; Center for Clinical Trial, Research, & Implementation Science (CCTRIS), College of Medicine, University of Lagos, Lagos, Nigeria., John-Olabode SO; Department of Haematology & Blood Transfusion, College of Medicine, University of Lagos, Lagos, Nigeria., Soibi-Harry AP; Department of Obstetrics & Gynaecology, Lagos University Teaching Hospital, Surulere, Lagos, Nigeria., Okoro AC; Department of Obstetrics & Gynaecology, Lagos University Teaching Hospital, Surulere, Lagos, Nigeria., Adejimi AA; Department of Community Health & Primary Care, College of Medicine, University of Lagos, Lagos, Nigeria., Ademuyiwa IY; Department of Nursing Science, College of Medicine, University of Lagos, Lagos, Nigeria., Osunwusi B; Department of Obstetrics & Gynaecology, Lagos University Teaching Hospital, Surulere, Lagos, Nigeria., Adelabu H; Center for Clinical Trial, Research, & Implementation Science (CCTRIS), College of Medicine, University of Lagos, Lagos, Nigeria., Salako O; Department of Radiation Biology, Radiotherapy & Radiodiagnosis, College of Medicine, University of Lagos, Lagos, Nigeria. |
| المصدر: | Future science OA [Future Sci OA] 2023 Aug 28; Vol. 9 (10), pp. FSO897. Date of Electronic Publication: 2023 Aug 28 (Print Publication: 2023). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Future Science Group Country of Publication: England NLM ID: 101665030 Publication Model: eCollection Cited Medium: Print ISSN: 2056-5623 (Print) Linking ISSN: 20565623 NLM ISO Abbreviation: Future Sci OA Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: London : Future Science Group, [2015]- |
| مستخلص: | Purpose: This study investigated the prognostic performance of the systemic immune-inflammation index (SII) in patients with epithelial ovarian cancer (EOC) in Lagos, Nigeria. Methods: We performed a secondary analysis of the data of 91 women who had treatment for EOC between 2009 and 2018. The associations between pretreatment SII and survivals were tested. Results: Pretreatment SII more than 610.2 was a significant independent predictor of reduced progression-free survival (HR = 2.68; 95% CI, 1.17 to 6.09) while SII greater than 649.0 was a significant independent predictor of reduced 3-year overall survival (HR = 2.01; 95% CI, 1.01 to 3.99). Conclusion: These findings suggest that high SII may be a potential prognostic indicator and useful marker for more intensive surveillance and design of personalized treatment in patients with EOC. Competing Interests: The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. (© 2023 The Authors.) |
| References: | Cancer Manag Res. 2018 Dec 05;10:6685-6693. (PMID: 30584363) Case Rep Oncol. 2019 Sep 25;12(3):728-736. (PMID: 31616281) Health Sci Rep. 2022 Jul 07;5(4):e717. (PMID: 35821892) J Gynecol Oncol. 2018 Sep;29(5):e65. (PMID: 30022629) Semin Immunol. 2016 Apr;28(2):187-96. (PMID: 27067179) Niger J Clin Pract. 2020 Aug;23(8):1141-1147. (PMID: 32788493) Int J Gynecol Cancer. 2015 Mar;25(3):416-22. (PMID: 25647256) Int J Mol Sci. 2019 May 25;20(10):. (PMID: 31130614) Int J Clin Oncol. 2023 Feb;28(2):314-320. (PMID: 36417028) Int J Gynaecol Obstet. 2021 Oct;155 Suppl 1:61-85. (PMID: 34669199) Cell. 2011 Mar 4;144(5):646-74. (PMID: 21376230) Inflamm Res. 2019 Apr;68(4):247-260. (PMID: 30680411) Int J Gynaecol Obstet. 2018 Oct;143 Suppl 2:118-130. (PMID: 30306588) Adv Exp Med Biol. 2020;1224:1-20. (PMID: 32036601) JCO Glob Oncol. 2021 Jan;7:89-98. (PMID: 33449803) CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338) Cureus. 2021 Jul 16;13(7):e16429. (PMID: 34422466) World J Surg Oncol. 2020 Aug 7;18(1):197. (PMID: 32767977) J Natl Compr Canc Netw. 2021 Feb 02;19(2):191-226. (PMID: 33545690) CA Cancer J Clin. 2023 Jan;73(1):17-48. (PMID: 36633525) Science. 2010 Apr 30;328(5978):562-4. (PMID: 20430990) Diagnostics (Basel). 2017 Mar 02;7(1):. (PMID: 28257098) J Immunother Cancer. 2019 Mar 28;7(1):85. (PMID: 30922400) Sci Rep. 2020 Oct 23;10(1):18190. (PMID: 33097745) Gynecol Oncol. 2019 Feb;152(2):259-264. (PMID: 30558974) Gland Surg. 2022 Oct;11(10):1639-1646. (PMID: 36353589) J Gynecol Obstet Hum Reprod. 2021 Jun;50(6):101849. (PMID: 32619726) Oncotarget. 2018 Oct 19;9(82):35293-35299. (PMID: 30450158) |
| معلومات مُعتمدة: | K43 TW011930 United States TW FIC NIH HHS |
| فهرسة مساهمة: | Keywords: Africa; EOC; SII; ovarian cancer; overall survival; prognosis; progression-free survival Local Abstract: [plain-language-summary] This study looked at how the systemic immune-inflammation index (SII) can predict the outcomes of patients with epithelial ovarian cancer (EOC). To do this, the data of 91 women who received treatment for EOC between 2009 and 2018 were analyzed. The study concluded that when the SII level was higher than 610.2 and 649.0, it was linked to a higher likelihood of EOC progressing sooner and of reduced survival at the 3-year mark, respectively. This suggests that a high SII might be a useful predictor to understand how EOC could progress and how well patients with EOC might survive. |
| تواريخ الأحداث: | Date Created: 20230927 Latest Revision: 20240422 |
| رمز التحديث: | 20240422 |
| مُعرف محوري في PubMed: | PMC10518822 |
| DOI: | 10.2144/fsoa-2023-0108 |
| PMID: | 37753357 |
| قاعدة البيانات: | MEDLINE |
PDF full text from Publisher 
Full Text Finder | تدمد: | 2056-5623 |
|---|---|
| DOI: | 10.2144/fsoa-2023-0108 |